| The next decade of immune checkpoint therapy P Sharma, BA Siddiqui, S Anandhan, SS Yadav, SK Subudhi, J Gao, ... Cancer discovery 11 (4), 838-857, 2021 | 447 | 2021 |
| Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma S Goswami, T Walle, AE Cornish, S Basu, S Anandhan, I Fernandez, ... Nature medicine 26 (1), 39-46, 2020 | 275 | 2020 |
| Immune checkpoint therapy—current perspectives and future directions P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui, P Singh, ... Cell 186 (8), 1652-1669, 2023 | 199 | 2023 |
| Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy S Goswami, I Apostolou, J Zhang, J Skepner, S Anandhan, X Zhang, ... The Journal of clinical investigation 128 (9), 3813-3818, 2018 | 188 | 2018 |
| Myeloid cell-targeted therapies for solid tumours S Goswami, S Anandhan, D Raychaudhuri, P Sharma Nature Reviews Immunology 23 (2), 106-120, 2023 | 99 | 2023 |
| ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC S Goswami, Y Chen, S Anandhan, PM Szabo, S Basu, JM Blando, W Liu, ... Science translational medicine 12 (548), eabc4220, 2020 | 89 | 2020 |
| The next decade of immune checkpoint therapy. Cancer Discov. 2021; 11: 838–857. doi: 10.1158/2159-8290 P Sharma, BA Siddiqui, S Anandhan, SS Yadav, SK Subudhi, J Gao, ... CD-20-1680, 2020 | 55 | 2020 |
| Mechanistic heterogeneity in contractile properties of α-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies TM Gupte, F Haque, B Gangadharan, MS Sunitha, S Mukherjee, ... Journal of Biological Chemistry 290 (11), 7003-7015, 2015 | 51 | 2015 |
| The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 P Sharma, BA Siddiqui, S Anandhan, SS Yadav, SK Subudhi, J Gao, ... | 15 | 2021 |
| Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade S Goswami, D Raychaudhuri, P Singh, SM Natarajan, Y Chen, C Poon, ... Nature Cancer 4 (10), 1455-1473, 2023 | 9 | 2023 |
| Targeting cd73 may improve immunotherapy efficacy in glioblastoma S Goswami, T Walle, AE Cornish, S Basu, S Anandhan, I Fernandez, ... Cancer discovery 10 (2), 175, 2020 | 2 | 2020 |
| 1305 Impact of Tet2-mutant clonal hematopoiesis on solid tumor immunology and response to checkpoint blockade S Herbrich, S Anandhan, P Sharma Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer. S Goswami, Y Chen, S Anandhan, PM Szabo, S Basu, JM Blando, W Liu, ... Journal of Clinical Oncology 39 (6_suppl), 488-488, 2021 | 1 | 2021 |
| In vivo CRISPR screening identifies PTDSS1 as a potential combinatorial target to improve immune checkpoint therapy response J Liu, S Anandhan, S Basu, Y Chen, S Goswami, A Nagarajan, S Herbrich, ... Cancer Research 83 (7_Supplement), 3277-3277, 2023 | | 2023 |
| Unveiling Immune Checkpoint Therapy Resistance Mechanisms In The Tumor Microenvironment Using High-Dimensional Analyses S Anandhan | | 2023 |
| 505 High-dimensional analyses of intratumoral myeloid cells highlights presence of distinct myeloid cell phenotypes in immune checkpoint-sensitive and resistant tumors S Anandhan, S Goswami, S Herbrich, Y Chen, P Sharma Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
